Advances in lung-on-a-chip platforms for nanotherapeutic evaluation and screening [0.03%]
基于器官芯片的纳米药物评价与筛选研究进展
Kimia Abedi,Jacqueline L Pavelick,Claudia C Dos Santos et al.
Kimia Abedi et al.
Improvements in drug solubility, targeting, and pharmacokinetics achieved through nanomedicine have driven the advancement of nanoparticle-based therapeutics. These formulations, administered either systemically or via pulmonary delivery, a...
Corrigendum to "Role of integrated cancer nanomedicine in overcoming drug resistance" [Adv. Drug Deliv. Rev. 65 (2013) 1784-1802] [0.03%]
关于“整合型癌症纳米药物在克服耐药性方面的作用”的勘误(发表于《药物递送评论》第65卷(2013)1784-1802页)
Arun K Iyer,Amit Singh,Srinivas Ganta et al.
Arun K Iyer et al.
Published Erratum
Advanced drug delivery reviews. 2026 Apr 4:115860. DOI:10.1016/j.addr.2026.115860 2026
Microfluidic platforms for precision delivery of therapeutic cells in regenerative and personalized medicine [0.03%]
用于再生医学和精确医学治疗性细胞精确定量输送的微流控平台
Maryam Sadat Mirlohi,Shima Akar,Kaveh Yazdani et al.
Maryam Sadat Mirlohi et al.
Regenerative medicine increasingly relies on therapeutic cells such as mesenchymal stem cells and induced pluripotent stem cells, and engineered cellular constructs to repair and restore damaged tissues. However, clinical translation is con...
Reaching new heights? Maximum subcutaneous injection volumes from a technical and clinical development strategy perspective [0.03%]
从技术和临床开发策略角度审视最大皮下注射剂量的新高度
Andrea Allmendinger,Hanns-Christian Mahler,Beate Bittner
Andrea Allmendinger
This manuscript reviews the evolving landscape of subcutaneous (SC) drug delivery, highlighting the increasing acceptance of administering higher volumes of biological products into SC tissue via injection or short-term infusion. Traditiona...
Towards clinical translation of nanomedicines: Formulation scale-up and model systems [0.03%]
纳米药物的临床转化：制剂放大和模型系统
Owen M Kelly,Andrew R Hanna,Addison K Byrne et al.
Owen M Kelly et al.
Non-viral nanomedicines, including nanoparticles (NPs) composed of lipids and polymers, represent a transformative approach to drug and gene therapy. However, clinical translation of these technologies is limited by two key barriers: the sc...
Sorosh Abdollahi,Fereshteh Vajhadin,Atefeh Rafiei et al.
Sorosh Abdollahi et al.
The gastrointestinal tract is a dynamic ecosystem where biophysical forces, enzymatic gradients, and microbial metabolism converge to govern the fate of orally administered therapeutics. These multifactorial interactions-spanning shear stre...
Self-assembled Nano-PROTACs: bridging chemical design and biological barriers in targeted protein degradation [0.03%]
自组装纳米型PROTACs：靶向蛋白降解的化学设计与生物屏障之间的桥梁
Ni-Yuan Zhang,Jian-Xiao Liang,Bei-Ning Hu et al.
Ni-Yuan Zhang et al.
Self-assembled Nano-PROTACs represent an emerging class of programmable supramolecular degraders that integrate targeted protein degradation with nanoscale delivery to overcome the intrinsic limitations of conventional PROTACs. Conventional...
Karim Azzag,Rita C R Perlingeiro
Karim Azzag
Cell therapy remains an attractive therapeutic option for the numerous genetic and non-genetic maladies affecting skeletal muscle. Since skeletal muscle is the largest tissue in the body, delivery has been notoriously challenging, but there...
Fiona Halbig,Simon Reiländer,Christoph Keßler et al.
Fiona Halbig et al.
Carbon monoxide (CO) has gained increasing attention as an endogenous gasotransmitter with potential therapeutic relevance. In preclinical studies, including acute lung injury, sepsis, transplantation, inflammatory bowel, and cardiovascular...
Protein stability and viscosity in molecularly crowded high-concentration biologics [0.03%]
高浓度生物药分子拥挤状态下的蛋白稳定性和粘度属性研究
Zhaoxi Zheng,Harshil K Renawala,W Peter Wuelfing et al.
Zhaoxi Zheng et al.
The paradigm for administering protein biologics is increasingly shifting from intravenous infusion to high-concentration subcutaneous delivery, driven by the desire for patient-centric, sometimes self-administered therapies to better manag...